ライフサイエンスコーパス: portosystemic

1 containing a migrated stent and facilitates portosystemic bypass and portal anastomosis.

2 nt, the liver transplant was completed under portosystemic bypass.

3 -Stage Liver Disease score (P < 0.001), more portosystemic collaterals (P = 0.01) and splenomegaly (P

4 viates portal hypertension (PH), severity of portosystemic collaterals and mesenteric angiogenesis, i

5 hnic hyperemia, increased portal inflow, and portosystemic collaterals formation, which may induce le

6 rtal hypertension (shunting of blood through portosystemic collaterals) and hepatic insufficiency res

7 rtal hypertension (shunting of blood through portosystemic collaterals) and hepatic insufficiency tha

8 rtal hypertension (shunting of blood through portosystemic collaterals) and hepatic insufficiency tha

9 rtal hypertension (shunting of blood through portosystemic collaterals) and hepatic insufficiency.

10 hyperdynamic circulation, angiogenesis, and portosystemic collaterals.

11 CBs may be targeted in the control of PH and portosystemic collaterals.

12 ver, TIPS is associated with higher rates of portosystemic encephalopathy and possibly higher costs.

13 Portosystemic encephalopathy is a consequence of both po

14 Portosystemic encephalopathy is a consequence of both po

15 Portosystemic encephalopathy is a consequence of both po

16 Another complication of cirrhosis, portosystemic encephalopathy, is a consequence of both p

17 H-related complications, such as ascites and portosystemic encephalopathy.

18 lications: variceal hemorrhage, ascites, and portosystemic encephalopathy.

19 lications: variceal hemorrhage, ascites, and portosystemic encephalopathy.

20 inical success was defined as a reduction of portosystemic gradient (PSG) and resolution of RA.

21 esults were compared, which included initial portosystemic gradient and Doppler measurements of blood

22 In 100 consecutive subjects, mean portosystemic gradient decreased from 24 to 11 mm Hg (me

23 eceptor were tested, and measurements of the portosystemic gradient were used to determine Gabsorp an

24 Differences in mean portosystemic gradients (PSGs) were evaluated by using t

25 Portosystemic pressure gradient (28 vs 11 cm H(2)O; P <

26 The portosystemic pressure gradient (PSG) was decreased to n

27 A portosystemic pressure gradient of > or =12 mm Hg is not

28 ination, portography with measurement of the portosystemic pressure gradient.

29 (77%) with and seven (23%) without elevated portosystemic pressure gradients.

30 r, eNOS (-/-) mice did develop a substantial portosystemic shunt (0.33% +/- 0.005% vs 84.53% +/- 0.19

31 2 +/- 0.003 vs 0.227 +/- 0.005 mL/min/g) and portosystemic shunt (0.47% +/- 0.01% vs 84.13% +/- 0.09%

32 150 min liver warm ischemia with or without portosystemic shunt (splenic-caval shunt).

33 Transjugular intrahepatic portosystemic shunt (TIPS) and surgical distal splenoren

34 lity and safety of transjugular intrahepatic portosystemic shunt (TIPS) as a treatment for BCS with d

35 thoracentesis and transjugular intrahepatic portosystemic shunt (TIPS) as second-line therapeutic op

36 ter placement of a transjugular intrahepatic portosystemic shunt (TIPS) correlates with the absence o

37 ailure (ELF) after transjugular intrahepatic portosystemic shunt (TIPS) creation in patients with cir

38 d complications of transjugular intrahepatic portosystemic shunt (TIPS) creation performed by using a

39 and bare stent in transjugular intrahepatic portosystemic shunt (TIPS) for cirrhotic portal hyperten

40 ibe the results of transjugular intrahepatic portosystemic shunt (TIPS) for the management of VOD aft

41 Recently, transjugular intrahepatic portosystemic shunt (TIPS) has been compared with ET in

42 the placement of a transjugular intrahepatic portosystemic shunt (TIPS) has been reported in up to 10

43 on human patients, transjugular intrahepatic portosystemic shunt (TIPS) has been worldwide considered

44 ients treated with transjugular intrahepatic portosystemic shunt (TIPS) have lower rebleeding rates c

45 s, and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) in a series of patients with

46 Transjugular intrahepatic portosystemic shunt (TIPS) in patients with portal hyper

47 cacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) in this population are unknow

48 The transjugular intrahepatic portosystemic shunt (TIPS) is an important treatment for

49 Transjugular intrahepatic portosystemic shunt (TIPS) is performed to treat some co

50 Transjugular intrahepatic portosystemic shunt (TIPS) is used in the management of

51 ansplantation, and transjugular intrahepatic portosystemic shunt (TIPS) on patient selection and outc

52 The effects of transjugular intrahepatic portosystemic shunt (TIPS) on portal hemodynamics, esoph

53 ty and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) performed semiemergently and

54 disease underwent transjugular intrahepatic portosystemic shunt (TIPS) placement for control of vari

55 Transjugular intrahepatic portosystemic shunt (TIPS) placement is effective in the

56 w before and after transjugular intrahepatic portosystemic shunt (TIPS) placement.

57 nts undergoing the transjugular intrahepatic portosystemic shunt (TIPS) procedure in patient groups w

58 cations related to transjugular intrahepatic portosystemic shunt (TIPS) stents found in the portal ve

59 converting failed transjugular intrahepatic portosystemic shunt (TIPS) to distal splenorenal shunt (

60 canalization (PVR)-transjugular intrahepatic portosystemic shunt (TIPS) to potentiate LT.

61 Additional transjugular intrahepatic portosystemic shunt (TIPS) was created to facilitate the

62 The transjugular intrahepatic portosystemic shunt (TIPS) was developed in the 1980s fo

63 ble on the role of transjugular intrahepatic portosystemic shunt (TIPS) with covered stents in patien

64 ainly treated with transjugular intrahepatic portosystemic shunt (TIPS).

65 for creation of a transjugular intrahepatic portosystemic shunt (TIPS).

66 atients undergoing transjugular intrahepatic portosystemic shunt (TIPS).

67 ant and five had a transjugular intrahepatic portosystemic shunt (TIPS).

68 paracentesis, and transjugular intrahepatic portosystemic shunt (TIPS)], but refractory hydrothorax

69 evaluate race as a predictor of undergoing a portosystemic shunt and LT and of dying in the hospital.

70 creased patency at transjugular intrahepatic portosystemic shunt creation.

71 Ppv), abdominal aortic blood flow (Qao), and portosystemic shunt determined 2 weeks later.

72 Portosystemic shunt enhances the tolerance of liver to w

73 Transjugular intrahepatic portosystemic shunt has become an accepted intervention

74 paracentesis with transjugular intrahepatic portosystemic shunt in the management of refractory asci

75 A transjugular intrahepatic portosystemic shunt is indicated when control of the ref

76 vein embolization, transjugular intrahepatic portosystemic shunt placement, balloon retrograde transv

77 The transjugular intrahepatic portosystemic shunt procedure is an effective interventi

78 who underwent the transjugular intrahepatic portosystemic shunt procedure.

79 ation or undergoing transvenous intrahepatic portosystemic shunt procedures.

80 A modified transjugular intrahepatic portosystemic shunt puncture set was introduced from the

81 previously placed transjugular intrahepatic portosystemic shunt underwent successful liver transplan

82 andomized trial of transjugular intrahepatic portosystemic shunt using covered stents and another pil

83 A transjugular intrahepatic portosystemic shunt was created in 14 young swine (weigh

84 tes, the adjusted odds ratios of receiving a portosystemic shunt were 0.37 (95% CI: 0.27-0.51) and 0.

85 l stenosis and the presence of a spontaneous portosystemic shunt whose successful endovascular treatm

86 Two patients had an extrahepatic portosystemic shunt, 17 had a portacaval shunt [subdivid

87 band ligation and transjugular intrahepatic portosystemic shunt, almost every acute variceal bleed c

88 us-1, previous LT, transjugular intrahepatic portosystemic shunt, and acute dialysis at LT.

89 e hepatocytes after liver warm ischemia with portosystemic shunt, compared with liver ischemia withou

90 ve been treated by transjugular intrahepatic portosystemic shunt, surgical exploration, or peritoneov

91 ter placement of a transjugular intrahepatic portosystemic shunt.

92 erance of liver to warm ischemia injury with portosystemic shunt.

93 is increase was significantly reversed after portosystemic shunt.

94 oes not preclude the creation of nonsurgical portosystemic shunt.

95 ion or stenosis and the presence of a patent portosystemic shunt.

96 ic artery flow, mesenteric vascular density, portosystemic shunting (PSS), intrahepatic angiogenesis,

97 ility, before/after transvenous intrahepatic portosystemic shunting (TIPS), and before/after yogurt t

98 catheter-directed thrombolysis, transjugular portosystemic shunting (TIPS), and liver transplantation

99 asty/thrombolysis, transjugular intrahepatic portosystemic shunting (TIPS), and orthotopic liver tran

100 th vehicle, JWH-015 significantly alleviated portosystemic shunting and mesenteric vascular density i

101 Liver disease or portosystemic shunting enhances th e sensitivity to endo

102 iography, which disclosed virtually complete portosystemic shunting in Fut2(-/-)(high) mice, discrete

103 c shunting in Fut2(-/-)(high) mice, discrete portosystemic shunting in Fut2(-/-)(low) mice, and no sh

104 ler hepatocyte size is the result of massive portosystemic shunting in null animals.

105 t2(-/-) mice is dominated by consequences of portosystemic shunting resulting in microcirculatory dis

106 with subsequent guidewire snaring to perform portosystemic shunting via femoral access.

107 Portosystemic shunting was demonstrated by portal angiog

108 Portosystemic shunting was shown by radiological methods

109 be successfully used as a bridge to surgical portosystemic shunting, as well as liver transplantation

110 modalities such as transjugular intrahepatic portosystemic shunting, hemodialysis, and in some cases,

111 amics, presence of CB receptors, severity of portosystemic shunting, mesenteric vascular density, vas

112 urements, including portal pressure (PP) and portosystemic shunts (PSS), and collected tissues for hi

113 Large spontaneous portosystemic shunts (SPSSs) have been previously sugges

114 Transjugular intrahepatic portosystemic shunts (TIPS) are a recent innovation in t

115 Transjugular intrahepatic portosystemic shunts (TIPS) are sometimes used to reduce

116 after creation of transjugular intrahepatic portosystemic shunts (TIPS) has been attributed to hemol

117 re of infection of transjugular intrahepatic portosystemic shunts (TIPS) has not been described previ

118 Transjugular intrahepatic portosystemic shunts (TIPS) have widened the use of port

119 ts with the use of transjugular intrahepatic portosystemic shunts (TIPS) in the treatment of these pa

120 Transjugular intrahepatic portosystemic shunts (TIPS) is a second-line treatment b

121 ectasia (GVE), to transjugular intrahepatic portosystemic shunts (TIPS) is not known.

122 Transjugular intrahepatic portosystemic shunts (TIPS) lower portal pressure and ha

123 Transjugular intrahepatic portosystemic shunts (TIPS) may worsen liver function an

124 ver the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase survival times o

125 ver the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase survival times o

126 linical utility of transjugular intrahepatic portosystemic shunts (TIPS) vis-a-vis total paracentesis

127 (CT) angiograms of transjugular intrahepatic portosystemic shunts (TIPS), helical CT angiography was

128 ing the patency of transjugular intrahepatic portosystemic shunts (TIPS).

129 s alternative treatment options to operative portosystemic shunts and devascularization procedures.

130 Despite these innovations, portosystemic shunts and esophagogastric devascularizati

131 Large spontaneous portosystemic shunts are associated significantly with m

132 Transjugular intrahepatic portosystemic shunts are frequently used in patients wit

133 The indications for and the results of portosystemic shunts done in the authors' institution si

134 Spontaneous portosystemic shunts greater than 10 mm in diameter, ide

135 ocumented the frequency of large spontaneous portosystemic shunts in patients with moderate or severe

136 Transjugular intrahepatic portosystemic shunts may be helpful in the treatment of

137 outflow obstruction classically treated with portosystemic shunts or liver transplantation.

138 Early transjugular intrahepatic portosystemic shunts placed in highly selected patients

139 Models described in rats using portosystemic shunts to achieve total ischemia have been

140 All extrahepatic portosystemic shunts, H-type portal-caval, portohepatic,

141 g and placement of transjugular intrahepatic portosystemic shunts, have improved preoperative assessm

142 Five had variceal bleeding, and 2 had portosystemic shunts.

143 , liver transplants, choledocholithiasis, or portosystemic shunts.

144 ctive placement of transjugular intrahepatic portosystemic shunts.

145 ctively treated by transjugular intrahepatic portosystemic stent shunt (TIPS).

146 or insertion of a transjugular intrahepatic portosystemic stent shunt (TIPS).

147 en a small covered transjugular intrahepatic portosystemic stent-shunt (TIPS) (8 mm; n = 90), or medi

148 udy was to compare transjugular intrahepatic portosystemic stent-shunt (TIPSS) with variceal band lig

149 de, but fluoroscopically placed intrahepatic portosystemic stents have recently been used with increa